BioSpace News Archive

Fast, reversible oxygen transport with minimal volume change is a key requirement for energy-efficient solid oxide fuel cells (SOFCs).

Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment for people living with cerebral cavernous malformations (CCM), a disease characterized by abnormally enlarged capillary cavities in the brain and spinal cord.

Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis.

Greenbrook TMS Inc. today announced that it has (i) completed a non-brokered private placement of common shares of the Company for aggregate gross proceeds of approximately US$6.25 million.

Tivic Health Systems, Inc. to Report Fiscal Year 2022 Financial Results on March 31st Via Conference Call and Webcast.

Today, the U.S. Food and Drug Administration issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications.

Kymanox Corporation, a professional services company exclusively serving the life science industry, announced the acquisition of Agilis Consulting Group.

JanOne, a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, announced the closing of its previously announced registered direct offering of 361,000 shares of the Company’s common stock at a purchase price of $1.17 per share of common stock priced at-the-market under Nasdaq rules.

HDT Bio Corp. today announced the peer-reviewed publication of preclinical data demonstrating that its self-amplifying replicon mRNA (repRNA) vaccines, delivered via HDT Bio’s proprietary LION nanoparticle formulation, provide robust maternal and neonatal immunogenicity against two pathogens with high mother-to-child transmission risk: HIV-1 and Zika virus (ZIKV).

Getinge’s iCast™ covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease.